NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 115 filers reported holding NURIX THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $459,000 | -47.3% | 32,769 | +8.9% | 0.01% | -60.9% |
| Q4 2021 | $871,000 | -7.5% | 30,081 | -4.3% | 0.02% | +35.3% |
| Q3 2021 | $942,000 | +245.1% | 31,442 | +278.8% | 0.02% | +240.0% |
| Q4 2020 | $273,000 | -13.1% | 8,300 | -7.8% | 0.01% | -44.4% |
| Q3 2020 | $314,000 | – | 9,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |